Alnylam Pharmaceuticals (ALNY) EPS (Weighted Average and Diluted) (2019 - 2025)
Historic EPS (Weighted Average and Diluted) for Alnylam Pharmaceuticals (ALNY) over the last 9 years, with Q3 2025 value amounting to $1.84.
- Alnylam Pharmaceuticals' EPS (Weighted Average and Diluted) rose 31149.43% to $1.84 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.24, marking a year-over-year increase of 10919.54%. This contributed to the annual value of -$2.18 for FY2024, which is 3817.59% up from last year.
- According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' EPS (Weighted Average and Diluted) is $1.84, which was up 31149.43% from -$0.51 recorded in Q2 2025.
- Over the past 5 years, Alnylam Pharmaceuticals' EPS (Weighted Average and Diluted) peaked at $1.84 during Q3 2025, and registered a low of -$3.32 during Q3 2022.
- In the last 5 years, Alnylam Pharmaceuticals' EPS (Weighted Average and Diluted) had a median value of -$1.4 in 2023 and averaged -$1.12.
- Over the last 5 years, Alnylam Pharmaceuticals' EPS (Weighted Average and Diluted) had its largest YoY gain of 31149.43% in 2025, and its largest YoY loss of 29230.77% in 2025.
- Alnylam Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarter) stood at -$2.18 in 2021, then increased by 23.01% to -$1.68 in 2022, then surged by 34.3% to -$1.1 in 2023, then surged by 40.55% to -$0.66 in 2024, then soared by 380.41% to $1.84 in 2025.
- Its EPS (Weighted Average and Diluted) was $1.84 in Q3 2025, compared to -$0.51 in Q2 2025 and -$0.44 in Q1 2025.